JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

CLINICAL GASTROENTEROLOGY

    1. Gamaleya Federal Research Centre for Microbiology and Immunology of the Ministry of Public Health (Moscow, Russian Federation)
    2. Botkin Hospital of Moscow Department of Public Health; Sechenov the First Moscow Medical University of the Ministry of Public Health (Moscow, Russian Federation)

    Keywords:Helicobacter pylori,biofilm,scanning electron microscopy

    Abstract:Using scanning electron microscopy, the ability of reference and freshly isolated Helicobacter pylori strains to form biofilm under cultivation on abiotic surfaces and in natural conditions was studied. It was shown that both types of strains were capable of biofilm formation in vitro, although reference strains synthesized less pronounced exocellular matrix and flagella than freshly isolated strains. Bio-film also was detected in specimens of antral mucosa under duodenal ulcer. Most often Helicobacter pylori biofilms were detected near the mouths of the gastric glands. The structure of matrix surface of such biofilms looked inhomogeneous in different parts of the epithelial layer.

      1. Eusebi L.H., Zagari R. M., Bazzoli F. Epidemiology of Helicobacter pylori infection // Helicobacter. - 2014. - v. 19 (Suppl. 1). - P. 1-5.
      2. Amieva M. R., El-Omar E. M. Host-bacterial interactions in Helicobacter pylori infection // Gastroenterology. - 2008. - v. 134. - P. 306-323.
      3. Wroblewski L.E., Peek R. M., Wilson K. T. Helicobacter pylori and gastric cancer: factors that modulate disease risk // Clin. Microbiol. Rev. - 2010. - v. 23. - P. 713-739.
      4. Shiota S., Suzuki R., Yamaoka Y. The significance of virulence factors in Helicobacter pylori // J. Dig. Dis. - 2013. - v. 14. - No. 7. - P. 341-349.
      5. Sgouras D.N., Trang T. T.H., Yamaoka Y. Pathogenesis of Helicobacter pylori infection // Helicobacter. - 2015. - v. 20. No. 1. - P. 8-16.
      6. Salama N.R., Hartung M. L., Müller A. Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori // Nat. Rev. Microbiol. - 2013. - v. 11. - No 6. - P. 385-399.
      7. Rhee K.H., Park J. S., Cho M. J. Helicobacter pylori: bacterial strategy for incipient stage and persistent colonization in human gastric niches // Yonsei Med. J. - 2014. - v. 55. - No. 6. - P. 1453-1466.
      8. Cellini L. A chameleon-like approach to life // World J. Gastroenterol. - 2014. - 20 (19). - P. 5575-5582.
      9. Costerton J. W. Lewandowski Z., Caldwell D. E. et al. Microbial biofilms // Annu. Rev. Microbiol. - 1995. - v. 41. - P. 435-464.
      10. Costerton J. W., Cheng K.-J., Geesey G. G. et al. Bacterial biofilms in nature and disease // Annu. Rev. Microbiol. - 1987. - v. 49. - P. 711-745.
      11. Cole S., Harwood J., Lee R., She R., Guineyr D. G. Chracterization of monospecies biofilm formation by Helicobacter pylori // J. Bacteriol. - 2004. - v. 10. - P. 3124-3132.
      12. Carron M. A., Tran V. R., Sugawa C., Coticchia J. M. Identification of Helicobacter pylori biofilms in human gastric mucosa // J. Gastrointest. Surg. - 2006. - v. 10. - No. 5. - P. 712-717.
      13. Andersen L. P., Rasmussen L. Helicobacter pylori-coccoid forms and biofilm formation // FEMS Immunol. Med. Microbiol. - 2009. - v. 56. - No. 2. - P. 112-115.
      14. Zhukhovitsky V. G. Coccoid forms of Helicobacter pylori to be cut off with Occam’s razor! // Intern. J. Med. Microbiol. - 2001. - v. 291 (Suppl. 31). - abst. # K/19. - P. 99.
      15. Жуховицкий В. Г. Микробиологическая диагностика хеликобактериоза // Эксперимент. клин. гастроэнтерол. - 2008. - № 8. - С. 34-45.
     


    Full text is published :
    Zhukhovitsky V.G., Smirnova T.A., Shevlyagina N.V., Korzheva I.Yu. et al. HELICOBACTER PYLORI BIOFILM IN VITRO AND IN VIVO. Experimental and Clinical Gastroenterology Journal. 2017;141(05):14-19
    Read & Download full text

    1. Outpatient clinic N 3 of the Presidential Administration of the Russian Federation (Moscow, Russian Federation)
    2. Moscow clinical scientific center (Moscow, Russian Federation)

    Keywords:pregnancy,Helicobacter pylori,early toxicosis,vomiting of pregnancy,anemia

    Abstract:Aim of the study. To investigate the effect of Helicobacter pylori infection on pregnancy and its outcome. Material and methods. An observational study involving 200 pregnant women divided into 3 groups. The first group included 100 women suffering from diseases associated with H. pylori, in the second - 50 pregnant women with digestive diseases, but H. pylori negative, a third - 50 healthy women. Results. It has been shown that women infected with H. pylori, significantly more likely to have the non-developing pregnancy in history, higher duration and severity of early toxicity, the frequency and severity of anemia in pregnant women, as well as the incidence of vaginal candidiasis. However, the presence of H. pylori had no effect on outcome of pregnancy, fetal development and weight and neonatal growth indicators.

      1. Malfertheiner P., Megraud F., O’Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht V/ Florence Consensus Report // Gut. 2016 Oct 5. pii: gutjnl-2016-312288. doi: 10.1136/gutjnl-2016-312288. [Epub ahead of print]
      2. Бордин Д. С., Бяхов М. Ю., Федуленкова Л. В. «Серологическая биопсия» и скрининг рака желудка //Злокачественные опухоли 2014;2(9):30-36.
      3. Бурков С. Г., Бурдина Е. Г. Эрадикация инфекции хеликобактер пилори - краеугольный камень терапии язвенной болезни // Consilium Provisorum. 2005;2:27-29.
      4. Karaer A., Ozkan O., Ozer S. Gastrointestinal symptoms and Helicobacter pylori infection in early pregnancy. A seroepidemiologic study // Gynecol. Obstet. Invest. 2008; 66:44-46.
      5. Sandven I., Abdelnoor M., Wethe M. Helicobacter pylori infection and hyperemesis gravidarum. An institution-based case-control study // Eur. J. Epidemiol. 2008;23:491-498.
      6. Clark SM, Dutta E, Hankins GD. The outpatient management and special considerations of nausea and vomiting in pregnancy // Semin Perinatol. 2014;38(8):496-502.
      7. Kazemzadeh M, Kashanian M, Baha B, Sheikhansari N. Evaluation of the relationship between Helicobacter Pylori infection and Hyperemesis Gravidarum // Med J Islam Repub Iran. 2014;28:72.
      8. Boltin D, Perets TT, Elheiga SA, Sharony A, Niv Y, Shamaly H, Dickman R. Helicobacter pylori infection amongst Arab Israeli women with hyperemesis gravidarum - a prospective, controlled study // Int J Infect Dis. 2014;29:292-295.
      9. Poveda GF, Carrillo KS, Monje ME, Cruz CA, Cancino AG. Helicobacter pylori infection and gastrointestinal symptoms on Chilean pregnant women // Rev Assoc Med Bras. 2014;60(4):306-310.
      10. Niemeijer MN, Grooten IJ, Vos N, Bais JM, van der Post JA, Mol BW, Roseboom TJ, Leeflang MM, Painter RC. Diagnostic markers for hyperemesis gravidarum: a systematic review and metaanalysis // Am J Obstet Gynecol. 2014;211(2):150.e1-15.
      11. Cardaropoli S, Rolfo A, Todros T. Helicobacter pylori and pregnancy-related disorders // World J Gastroenterol. 2014;20(3):654-664.
      12. Duley L. The global impact of pre-eclampsia and eclampsia // Semin Perinatol 2009; 33:130-137.
      13. Ponzetto A, Cardaropoli S, Piccoli E, Rolfo A, Gennero L, Kanduc D, et al. Pre- eclampsia is associated with Helicobacter pylori seropositivity in Italy // J Hypertens 2006; 24:2445-2449.
      14. Franceschi F, Di Simone N, D’Ippolito S, Castellani R, Di Nicuolo F, Gasbarrini G, et al. Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia? // Helicobacter 2012; 17:426-434.
      15. Tersigni C, Franceschi F, Todros T, Cardaropoli S, Scambia G, Di Simone N. Insights into the Role of Helicobacter pylori Infection in Preeclampsia: From the Bench to the Bedside // Front Immunol. 2014;5:484
      16. Лазебник Л. Б., Васильев Ю. В., Щербаков П. Л., Хомерики С. Г., Машарова А. А., Бордин Д. С., Касьяненко В.И, Дубцова Е. А. Helicobacter pylori: распространенность, диагностика, лечение //Экспериментальная и клиническая гастроэнтерология 2010;2:3-7.
      17. Барышникова Н. В., Ткаченко Е. И., Успенский Ю. П. Современные аспекты состояния проблемы Helicobacter pylori - ассоциированных заболеваний / в книге Гастроэнтерология. Болезни взрослых / под общ. ред. Л. Б. Лазебника, П. Л. Щербакова. - М.: МК, 2011 - С. 103.
      18. Цуканов В. В., Хоменко О. В., Ржавичева О. С., Буторин Н. Н., Штыгашева О. В., Маады А. С., Бичурина Т. Б., Амельчугова О. С. Распространенность Helicobacter pylori и ГЭРБ у монголоидов и европеоидов восточной Сибири // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2009;19(3):38-41.
     


    Full text is published :
    Burkov S.G., Bordin D.S., Sharapova E.I., Markina N.F. INFLUENCE OF HELICOBACTER PYLORI ON CLINICAL COURSE OF PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):20-23
    Read & Download full text

    1. State funded medical institution “City clinical hospital № 15 named after O. M. Filatov” Department of healthcare of Moscow (Moscow, Russian Federation)
    2. State funded institution of higher professional education “Moscow State Medical and Dental University of A. I. Evdokimov” (Moscow, Russian Federation)

    Keywords:Crohn’s disease,infliximab,infliximab concentration in blood serum,infliximab pharmacokinetics,anticytokine therapy,mesenchymal stromal cells of the bone marrow

    Abstract:The therapeutic effect of infliximab (INFL) in Crohn’s disease (CD) patients receiving anticytokine therapy depends on the concentration of the medication in the blood serum. When INFL concentration in the blood serum is high (more than 20 μg/ml) the clinical and endoscopic remission of CD is observed in the patients. Upon the second administration INFL is not accumulated in the organism. After the induction course of INFL the level of the medication in the blood serum increases (more than 45 μg/ml), further its serological concentration gradually decreases approaching the values below the minimum. The transplantation of mesenchymal stromal cells of the bone marrow contributed to the increase of INFL level in the blood serum and to the recovery of sensitivity to INFL.

      1. Насонов Е. Л. Фактор некроза опухоли -α новая мишень для противовоспалительной терапии ревматоидного артрита // РМЖ.-2000.-т.8.-№ 17.-с.718-722.
      2. Насонов Е. Л. Моноклональные антитела к фактору некроза опухоли -α в ревматологии // РМЖ.-2003.-№ 7.-с.718-722.
      3. Сагынбаева В. Э., Лазебник Л. Б., Князев О. В., Ефремов Л. И. Антитела к инфликсимабу и к антигенам HLA-I и II класса как свидетели иммунного ответа на биолгическую терапию воспалительных заболеваниях кишечника // Экспер. и клинич. гастроэнтер. 2011. № 12. -с. -49-53.
      4. Keating G. M., Perry C. M. Infliximab: an updated review of its use in Crohns disease and rheumatoid arthritis, BioDroge.-2002/-16 (2).111-48.
      5. Han P. D., Cohen R. D. Managing immunogenic responses to infliximab: treatment implications for patients with Crohns disease. Gruds.-2004.-64(16): 1767-77.
      6. Remicade approved for children with Crohns disease. FDA Comsun.-2006 Jul-Aug.-40(4).-6.
      7. Халиф И. Л. Биологическая терапия болезнь Крона // Методическая рекомендация. Выпуск 1. -2011. - Стр. 20.
      8. Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and of infliximab // Clin pharmacokinet 2007; 46: 645-60.
      9. Fasanmade AA., Adedokun OJ., Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis // Int J Clin Pharmacol Ther 2010; 48: 297-308.
      10. Fasanmade AA., Adedokun OJ., Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis // Eur J Clin Pharmacol 2009; 65: 1211-28
      11. Pollono EN., Lopez-Olivo MA., Iopez JA, et al. A systematic review of the effect of TNF-alpha antagonist on lipid profiles in patients with rheumatoid arthritis// Clin Rheum Dis 2010; 69: 817-21
      12. Xu Z., Seitz K., Fasanmade A., Ford J., Williamson P., Xu W., Davis H. M., Zhou H. Population pharmacokinetics of infliximab in patients with ankylosind spondylitis, J Clin Pharmacol.-2008. Jun; 48 (6): 681-95. Epub 2008 Apr 9.
      13. Elliott M. J., Maini R. N., Feldmann M., Long -Fox A., Chariles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis, Lancet.-1994.-Oct 22.-344 (8930).-1125-7).
     


    Full text is published :
    Sagynbaeva V.E., Lazebnik L.B., Golovanova E.V. THERAPEUTIC CONCENTRATION OF INFLIXIMAB IN THE BLOOD SERUM OF CROHN’S DISEASE PATIENTS RECEIVING ANTICYTOKINE THERAPY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):24-28
    Read & Download full text

    1. Federal State Budgetary Educational Institution of Higher Education “National Research Ogarev Mordovia State University” (Saransk, Russian Federation)
    2. Federal State Health Institution Clinical Hospital 50 Federal Medical - Biological Agency Russian, clinic 1, Women’s Center (Saransk, Russian Federation)

    Keywords:drug-induced hepatitis,pregnancy,medicines,biochemical activity of drug-induced hepatitis

    Abstract:Purpose of the study. To characterize drug-induced hepatitis in pregnant women. Materials and methods: a clinical examination, a retrospective analysis of the exchange of cards and 67 birth stories of women. Results. Drug-induced hepatitis often diagnosed at 39 weeks of gestation. Overweight and comorbidities biliary system increases the biochemical activity of drug-induced hepatitis. The clinical picture is dominated by asymptomatic version of the flow, but monosemeiotic option complaining of itchy skin, accompanied by higher rates of liver transaminases. Among biochemical syndromes prevailed cytolytic and cholestatic options, and the degree of activity of transaminases usually defined as the minimum and reasonable. Drug-induced hepatitis in pregnant women developed in patients receiving combinations of 5 or more drugs, which included vitamin - mineral complexes, progestogens, folic acid preparations, iodine preparations. The degree of hepatitis activity was in direct proportion to the number of drugs taken.

      1. Еремина Е. Ю., Герасименко И. В. Лекарства и печень. // Алфавит. - 2013. - № 2. - С. 18-22.
      2. Еремина Е. Ю., Герасименко И. В., Герасименко А. В. Лекарственные поражения печени у беременных. // Медицинский альманах. - 2013. - № 1. - С. 55-59.
      3. Ozsvár Z., Solymossi Z., Monostory K. Methyldopa-induced acute reactive hepatitis in pregnancy, drug-metabolizing capacity of the liver / // Orv Hetil. - 2010. - 151(11):457-61.
     


    Full text is published :
    Gerasimenko I.V., Chernova O.V. DRUG-INDUCED HEPATITIS IN PREGNANT WOMEN. Experimental and Clinical Gastroenterology Journal. 2017;141(05):29-32
    Read & Download full text